STYLAGE® S BI-FLEX® with Lidocaine

STYLAGE® S BI-FLEX® with Lidocaine is an injectable HA dermal filler manufactured by Laboratories VIVACY in France, formulated for fine line correction and superficial wrinkle treatment. It uses IPN-Like Technology™ and the updated BI-FLEX® syringe system, formerly known as Bi-SOFT®, and contains 16mg/g HA, 9mg/mL mannitol, and 3mg/mL lidocaine. The STYLAGE® range is CE-marked for use in the EU, subject to local regulatory requirements.

STYLAGE® S BI-FLEX® with Lidocaine is used for fine line correction, superficial wrinkle treatment, periorbital and perioral lines, skin texture refinement, and the superficial component of nasolabial folds and marionette lines. It is not indicated for deep volumization. Use should be limited to trained aesthetic professionals and guided by treatment area, tissue quality, and clinical assessment.

Longevity varies by treatment area, injection technique, skin type, lifestyle, and condition of the patient’s skin. Mannitol may help limit oxidative HA degradation and support product longevity, but duration should be communicated to patients as an expected range rather than a fixed outcome. Practitioners should refer to the product IFU for manufacturer guidance on duration.

BI-FLEX® is the rebranded successor to Bi-SOFT®, updated to offer improved ergonomics, injection precision, and safety for practitioners and patients alike. The current BI-FLEX® version is identified by its soft purple-and-white packaging. It should be understood as an improvement in the delivery system, not a change to the product’s formulation or HA concentration.

STYLAGE® products are CE-marked and clinically used in professional aesthetic medicine. For superficial-plane correction specifically, STYLAGE® S BI-FLEX® with Lidocaine offers IPN-Like Technology™ for gel stability in high-movement areas, mannitol to support longevity, and the precision of the updated BI-FLEX® syringe system. Suitability should be determined by clinical assessment of the patient’s skin condition, treatment area, and correction objective.

The STYLAGE® range is CE-marked for use in the EU, but the current US FDA status should be verified before procurement or use. FDA approval for dermal fillers is product- and indication-specific. Practitioners should confirm jurisdiction-specific regulatory status before clinical discussion, procurement, or administration.

Common side effects include redness, swelling, tenderness, bruising at the injection site, pain, itching, or firmness. These reactions typically resolve within a few days. Worsening pain, change in skin color, blanching, livedo, or visual symptoms require urgent clinical evaluation.

Citations

1. Ramos-E-Silva M, Fonteles LA, Lagalhard CS, Fucci-da-Costa AP. STYLAGE®: a range of hyaluronic acid dermal fillers containing mannitol. Physical properties and review of the literature. Clin Cosmet Investig Dermatol. 2013;6:257-261. Published 2013 Oct 23. doi:10.2147/CCID.S35251
2. Micheels P, Porcello A, Bezzola T, et al. Clinical Perspectives on the Injectability of Cross-Linked Hyaluronic Acid Dermal Fillers: A Standardized Methodology for Commercial Product Benchmarking with Inter-Injector Assessments. Gels. 2024;10(2):101. Published 2024 Jan 26. doi:10.3390/gels10020101
3. Pantermehl S, Foth A, Meyer E, Barbeck M, Jung O. In Vitro Cytocompatibility Analysis and Comparison of Different Hyaluronic Acid Fillers for Minimally Invasive Esthetics. In Vivo. 2024;38(4):1621-1635. doi:10.21873/invivo.13612

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.